Abstract Search

ea0021p204 | Endocrine tumours and neoplasia | SFEBES2009

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O⁶-methylguanine-DNA methyltransferase expression

Burton Hannah , Annamalai Anand K , Dean Andrew , Kovacs Kalman , Antoun Nagui , Kirollos Ramez W , Simpson Helen L , Jeffries Sarah J , Burnet Neil G , Gurnell Mark

Background: Pituitary carcinoma occurs in ~0.2% of resected pituitary tumours, and carries a poor prognosis (mean survival <4 years), with standard chemotherapeutic regimens showing limited efficacy. However, recent evidence suggests that temozolomide, an orally active alkylating agent used principally in the management of glioblastoma, may also be effective in controlling aggressive/invasive pituitary adenomas/carcinomas. Low levels of expression of the DNA-repair enzyme ...

0 shares

Endocrine Abstracts

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O⁶-methylguanine-DNA methyltransferase expression

BiosciAbstracts

Endocrine Abstracts

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O6-methylguanine-DNA methyltransferase expression

BiosciAbstracts

Temozolomide-induced regression of hepatic metastases in a pituitary corticotroph carcinoma with low O⁶-methylguanine-DNA methyltransferase expression